Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Our Research » Research Programs
  • Research Programs
    • Taclantis® (PICS)
    • Baclofen GRS
    • PDP – 716
    • SDN - 037
    • SCO - 088
    • SDN - 021
    • SCD - 044
    • SCC - 138
    • SDN - 118
    • SCO - 120

PDP - 716

Brimonidine is the one of the most commonly used treatment of glaucoma and ocular hypertension.

Brimonidine is dosed TID in the US and BID or TID in other countries. Due to the dose intensive schedule, patient adherence to Brimonidine therapy is low. Studies on individual adherence with Brimonidine ophthalmic solution for the treatment of glaucoma have shown that adherence of patients was highly variable and pharmacologically insufficient for more than two thirds of the patients when they were asked to administer Brimonidine eye drops multiple times in a day1, 2. These findings demonstrate the necessity to develop new strategies to improve compliance in glaucoma therapy with Brimonidine.

SPARC is developing novel once-a-day Brimonidine Eye Drops using proprietary TearActTM Technology which would provide controlled and continuous delivery of drug thereby increasing bioavailability and duration of action hence improve individual adherence and compliance. 

Following successful completion of Phase 2 proof-of-concept study, SPARC submitted IND in Q4 FY18. Phase 3 study has been initiated in Q1 FY19 with the aim of submitting NDA by Q4 FY20.

 

Graph
1. Acta Ophthalmol. 2011 Jun;89(4):e300-5., 2. J Glaucoma. 2011 Oct;20(8):502-8.

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits